Business Wire

Xsolla Launches Buy Button for Mobile Games to Help Developers Take Back Control of Their Revenue

Share

Xsolla, a global leader in video game commerce, today announced the launch of the Xsolla Buy Button for Mobile Games, a direct-to-consumer payment solution designed to help mobile developers keep more of what they earn by saving on traditional platform fees. This release follows a significant U.S. court ruling on April 30, 2025, prohibiting Apple from blocking external payment links or charging commissions on third-party U.S. storefronts, giving developers new opportunities to connect with players and grow revenue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507955570/en/

(Graphic: Xsolla)

With the Buy Button for Mobile Games, game developers can embed direct payment links inside their games, leading to a browser-based checkout powered by Xsolla Web Shop and Xsolla Pay Station. This checkout supports the sale of virtual items, currencies, and bundles, delivering a seamless player experience while avoiding up to 30% in platform fees.

Developers can now create a quick-to-create external link within their video game experience on an iOS mobile device. When a player taps the link, it opens up a streamlined browser-based checkout delivering a secure, pre-authenticated, frictionless purchase experience, allowing users to purchase their favorite game in fewer clicks. In addition, mobile game developers can also gain access to catalog synchronization, loyalty tools, personalized offers, and integration options required to manage the offers provided in the external link with little to no custom development.

Key Benefits of the Xsolla Buy Button:

  • Zero Platform Commission: Reclaim up to 30% of your revenue by saving on platform fees, minus standard payment processing costs.
  • Implementation: Under the April 2025 U.S. court ruling, developers can connect external payment links in-app without platform interference.
  • Frictionless One-Tap Purchase Flow: Players can purchase specific items directly from in-game offers using autofill and one-tap methods, delivering a seamless checkout experience native to the game.
    Simplified Tax and Compliance: Xsolla is the Merchant of Record, handling global tax calculation, collection, and remittance. Third-party tax solutions are unnecessary.
  • Loyalty and Player Rewards: Boost retention and engagement with loyalty programs and personalized reward options tied to player behavior within the game experience, whether in-app or online. This feature also enables issuing prepaid gift cards and parental control integration for all purchases.
  • LiveOps Sync: Align web-based promotions with in-game events, seasonal content, and player-achieved milestones to maximize the relevancy and impact of the offers provided to players.
  • Parental Control and Gift Cards: Built-in parental control and gift cards are available worldwide.
  • Multi-Channel Commerce: Extend monetization beyond the app to the web, Discord, Telegram, and other community channels where players engage.

“This court decision is a turning point for mobile game developers in the US and around the world. The Buy Button is available today through the Xsolla Web Shop,” stated Chris Hewish, Chief Strategy Officer at Xsolla. “Developers can register through the Xsolla Publisher account, use the Instant Web Shop template, and generate links in minutes without requiring custom coding. This rollout reinforces Xsolla’s commitment to building flexible, global commerce tools empowering developers to succeed and scale their business across multiple platforms.”

This offering is a game changer by giving mobile game developers control of their monetization, the ability to build closer relationships with their players, and the confidence to grow their business with long-term sustainability without previously imposed constraints.

Web Shop Integration Guide: xsolla.pro/webshop-integration

Buy Button for Mobile Games Integration Guide: xsolla.pro/buybutton

Mobile SDK Integration Guide: xsolla.pro/mobile-sdk-guide

View Video: youtu.be/Aj6gtHw5BFQ

About Xsolla

Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.

For more information, visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507955570/en/

Contacts

Media Contact

Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye